Company: PTPI
Filing Date: 2025-02-13
Form Type: S-1/A
Source: 0001410578-25-000122
Chunk: 207

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-13
Form: S-1/A
Chunk 207
---
 
   ​ | ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ | ​       
 ​       
 ​       
 ​       
 ​       
 Capital 
 ​       |                  ​ 
                  ​ 
                  ​ 
                  ​ 
 Additional Paid-in 
                  ​ | ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ | ​           
 ​           
 ​           
 ​           
 Accumulated 
 Deficit     
 ​           |           ​ 
           ​ 
           ​ 
           ​ | ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ | ​     
 ​     
 ​     
 ​     
 ​     
 Total 
 ​     |           ​ 
           ​ 
           ​ 
           ​ 
           ​ 
           ​ |
|:-------------------------------------------------------------------------------------------------------------|:--|------------:|:--|:------------|-----------:|:--|:--|----------:|:--|:-------|----:|:--|:--------|-------------------:|:--|:------------|------------:|:--|:------|------------:|
| Balance, December 31, 2022                                                                                   | ​ |           — | ​ | $           |          — | ​ | ​ | 2,079,387 | ​ | $      | 208 | ​ | $       |        107,428,652 | ​ | $           | -90,726,393 | ​ | $     |  16,702,467 |
| Stock-based compensation expense                                                                             | ​ |           — | ​ | ​           |          — | ​ | ​ |    49,645 | ​ | ​      |   5 | ​ | ​       |            417,225 | ​ | ​           |           — | ​ | ​     |     417,230 |
| Shares issued for vested RSU’s                                                                               | ​ |           — | ​ | ​           |          — | ​ | ​ |    40,233 | ​ | ​      |   3 | ​ | ​       |                 -3 | ​ | ​           |           — | ​ | ​     |           — |
| Issuance of Series A Preferred Stock in private placement, net of discount and transaction costs $15,000,003 | ​ |      15,000 | ​ | ​           |          — | ​ | ​ |         — | ​ | ​      |   — | ​ | ​       |                  — | ​ | ​           |           — | ​ | ​     |           — |
| Accrual of Series A Preferred Stock and